Mer­ri­mack re­cruits Sanofi vet Richard Pe­ters for the top job; Ob­sE­va and Brae­burn de­tail their IPO shots

• Now that Mer­ri­mack Phar­ma­ceu­ti­cals $MACK has auc­tioned off its sole com­mer­cial drug to Ipsen and fo­cused square­ly on a set of top clin­i­cal can­di­dates, the Cam­bridge, MA-based biotech has re­cruit­ed long­time in­dus­try vet­er­an Richard Pe­ters to take the helm. The Har­vard-trained physi­cian is com­ing over from Sanofi Gen­zyme, where he was SVP of glob­al rare dis­eases, a $3 bil­lion per year busi­ness. “With the sup­port of the Board of Di­rec­tors and the ex­pect­ed near-term in­fu­sion of cap­i­tal, sev­er­al com­pelling clin­i­cal as­sets are now primed to re­al­ize their full po­ten­tial,” said Pe­ters in a state­ment. “To­geth­er with the rest of the man­age­ment team, we plan on con­tin­u­ing to take sub­stan­tial steps to grow our ro­bust pipeline to its full po­ten­tial, with an eye to­ward ear­ly da­ta read-outs, to max­i­mize val­ue cre­ation for pa­tients and stock­hold­ers.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER